NOA also includes other formulations of cystamine and cysteamine. The patent application 11/990,869 covers the use of any composition of cysteamine or cystamine that provides increased delivery to
PSI-7977 is Pharmasset’s experimental nucleotide polymerase inhibitor and TMC435 is an experimental protease inhibitor of Tibotec. In the trial, the companies expect to investigate the pharmacokinetics, safety and
With this approval, the company has received approval for its complete product line of amlodipine / benazepril. The US subsidiary of Lupin Limited, LPI’s amlodipine / benazepril capsules
The funding will be used to further develop Ark’s lentiviral vector production technology using baculoviruses (Baculo-lentiviral) to achieve required scale and GMP quality for clinical use. Additionally, Ark
Additionally, Almirall has also received German approval for Actikerall as a treatment hyperkeratotic actinic keratosis (grade I/II) in adult patients. Almirall is set to launch Actikerall in German
The study investigated the safety and efficacy of Pregabalin (CI-1008) in the treatment of fibromyalgia. The results of the trial showed reduction in the endpoint mean pain score
The company will use the money for advancing its two preclinical candidates – VA106483 for nocturia and VA111913 – as a treatment for dysmenorrhoea. The results from Phase
Chugai has licensed marketing and development rights for CSG452 to Roche in January 2007 as a treatment for type II diabetes. Roche’s decision was backed by the priority
The FDA’s decision was based on its inspection which it has conducted in February 2011 and identified significant violation of current good manufacturing practices at the plant, reported
APP Pharma‘s Nafcillin for injection, which is indicated for the treatment of infections caused by penicillinase-producing staphylococci, is the generic version of GlaxoSmithKline (GSK) marketed drug Nallpen and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.